Stockwinners Market Radar for August 05, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:54 EDT GAP Airports reports preliminary July passenger traffic down 62.3% y/y - GAP Airports announced preliminary terminal passenger traffic figures for the month of July 2020, compared to traffic figures for July 2019. For July 2020, the total number of terminal passengers at GAP's 14 airports decreased by 62.3%, compared to the same period of the previous year. Domestic passenger traffic decreased by 56.4%, while international passenger traffic decreased by 70.7%. With regard to the operations of our airports in Mexico, the Mexican Government has not issued any flight restrictions and airlines continue to increase the frequencies of their domestic and international flights. In the case of Jamaica, flight restrictions were lifted on June 15, 2020, with strict health safety protocols.

18:03 EDT California labor commissioner sues Uber and Lyft for 'wage theft' - "The Labor Commissioner's Office has filed separate lawsuits against transportation companies Uber (UBER) and Lyft (LYFT) for committing wage theft by misclassifying employees as independent contractors. Uber and Lyft have misclassified their drivers, which has deprived these workers of a host of legal protections in violation of California labor law, the lawsuits say. The goal of the lawsuits is to enforce California labor laws and to ensure that drivers are not misclassified as independent contractors. In 2018, the California Supreme Court's Dynamex ruling established the "ABC test" for determining whether a worker is an employee under various California labor laws. Assembly Bill 5, which went into effect on January 1, 2020, extended the ABC test to additional California labor laws. Under the ABC test, workers are considered employees unless they are free from control from the hiring entity, perform work outside of the hiring entity's usual business, and engage in an independently established trade or occupation," said a statement from the State of California Department of Industrial Relations. Reference Link

18:02 EDT CTO Realty Growth sells Austin, Texas property for $2.5M - CTO Realty Growth announced the closing of the sale of a property located in Austin, Texas leased to Carrabba's Italian Grill, for a sales price of approximately $2.5M, reflecting an exit cap rate of approximately 6.4%. The property is currently under an absolute net lease to Carrabba's with approximately 11 years remaining on the initial term of the lease. The proceeds are expected to be part of a future Section 1031 like-kind exchange. The company estimates a loss on the sale of approximately $94,000, or 2c per share, after tax. With the closing of this transaction, the company has over $36M of proceeds held in 1031 restricted cash accounts. Year to date, the company has completed the sale of six single-tenant net lease properties and one multi-tenant retail property, for an aggregate sales price of more than $49M.

17:45 EDT Inseego CFO Steve Smith to step down - On the company's quarter earnings call, Inseego CEO Dan Mondor announced that Steve Smith will be stepping down as CFO. Mondor added that Craig Foster will join the company as its new CFO, effective August 17. Foster previoulsy served as CFO of "several public and private" technology companies, the CEO said.

17:40 EDT Legend Biotech says China CDE recommends BTD for BCMA CAR-T cell therapy - Legend Biotech Corporation announced that the China Center for Drug Evaluation, National Medical Products Administration has recommended Breakthrough Therapy Designation for ciltacabtagene autoleucel, an investigational B-cell maturation antigen (BCMA) targeted chimeric antigen receptor (CAR) T-cell therapy being studied for the treatment of adults with relapsed or refractory multiple myeloma (RRMM). The BTD for cilta-cel (LCAR-B38M CAR-T cells) is based on the ongoing Phase 2 CARTIFAN-1 study being conducted in China (MMY2002, NCT03758417, CTR20181007), the ongoing Phase 1b/2 CARTITUDE-1 study of cilta-cel (JNJ-4528) being conducted in the US (MMY2001, NCT03548207) and Japan and the Phase 1, first-in-human LEGEND-2 study conducted in China (NCT03090659). Ciltacabtagene autoleucel (cilta-cel) refers to both LCAR-B38M CAR-T cells and JNJ-4528. LCAR-B38M CAR-T cell identifies the investigational product being studied in China and JNJ-4528 identifies the investigational product being studied outside of China, both of which are representative of the same CAR-T cell therapy. The BTD procedure is part of the recently revised Drug Registration Regulation which went into effect on July 1, 2020. The BTD process is designed to expedite the development and review of therapies that are intended for treatment of serious diseases for which there is no existing treatment and where preliminary evidence indicates advantages of the therapy over available treatment options.1 Cilta-cel is the first product that has been recommended for BTD in China.2 As per the working procedure for BTD (2020 No.82) issued by NMPA on July 8, 2020, CDE had completed the review and recommended to grant the BTD on August 4th, and BTD will be granted after 5 working days of publicity period (August 5 to 12) on the CDE website.

17:33 EDT National Bank announces 20c quarterly dividend - National Bank Holdings announced that its Board of Directors approved a cash dividend to shareholders. The quarterly cash dividend of twenty cents ($0.20) per share of common stock will be payable on September 15, 2020 to shareholders of record at the close of business on August 28, 2020.

17:29 EDT Cboe Global Markets reports July ADV across four option exchanges up 33% y/y - Reports: U.S. Equities total ADV across Cboe's four equities exchanges was up 48$ from July 2019; Global FX ADNV up 9% from July 2019.

17:25 EDT Pan American Silver sees FY20 CapEx $210M-$215M

17:23 EDT General Dynamics awarded $106.92M Navy contract - General Dynamics was awarded a $106.92M, firm-fixed-price contract for the execution of the USS Bataan FY20 selected restricted availability. This availability will include a combination of maintenance, modernization and repair of the USS Bataan. This contract includes options which, if exercised, will bring the cumulative value of this contract to $130.86M. Work will be performed in Norfolk, Virginia. This is a "long-term" non-docking availability and was solicited on a coast-wide basis without limiting the place of performance to the vessel's homeport. General Dynamics will provide the facilities and human resources capable of completing, coordinating and integrating multiple areas of ship maintenance, repair and modernization for USS Bataan. Work is expected to be completed by December 2021. FY20 operations and maintenance and 2020 other procurement funding in the amount of $106.92M will be obligated upon contract award and funds in the amount of $1.82M will expire at the end of the current fiscal year. This contract was competitively procured using full and open competition via the Federal Business Opportunities website and one offer was received in response to Solicitation No. N00024-19-R-4467. The Naval Sea Systems Command is the contracting activity.

17:18 EDT AVCtechnologies to acuire Ribbon's Kandy Communications business - American Virtual Cloud Technologies (AVCT) and Ribbon Communications (RBBN) announced they have entered into a definitive agreement for AVCtechnologies to acquire Kandy Communications, "an industry-leading proprietary, multi-tenant, highly scalable cloud communications platform," from Ribbon, in an all-stock transaction. Upon closing, the senior leadership team of Kandy and its personnel, composed of talented business and technology professionals, are expected to join AVCtechnologies. Under the agreement, AVCtechnologies will issue 13M shares of its common stock to Ribbon Communications. The transaction is expected to close in the second half of 2020 and is subject to standard regulatory review and receipt of the approval of AVCtechnologies' stockholders, AVCtechnologies' completion of an equity offering, as well as other customary closing conditions.

17:11 EDT Laredo sees completing 15-well package in Howard County during Q4 - Laredo now expects to complete a 15-well package in Howard County during Q4 of 2020.

17:05 EDT Aveo announces $2.8M development milestone earned from Kyowa Kirin - Aveo Oncology announced that it has earned a $2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. (Kyowa Kirin). The milestone relates to acceptance by the Japanese Pharmaceuticals and Medical Devices Agency of an investigational new drug (IND) application for tivozanib in a non-oncology indication being developed by Kyowa Kirin. "This milestone marks an important step forward for AVEO's non-oncology pipeline," said Michael Bailey, president and chief executive officer of AVEO. "We believe tivozanib's potential in non-oncology indications is significant, and we look forward to seeing Kyowa Kirin move this formulation into the clinic." Under the terms of AVEO's agreement with Kyowa Kirin, in addition to the previously-paid upfront payment of $25 million to AVEO and waiver of AVEO's obligation to make an $18 million milestone payment upon AVEO gaining U.S. marketing approval of tivozanib for renal cell carcinoma, and now the IND development milestone, Kyowa Kirin has also agreed to pay AVEO up to an additional $388 million in potential milestone payments upon the successful achievement of certain development, regulatory, and commercial objectives in non-oncology indications of tivozanib. Kyowa Kirin will also be obligated to make tiered royalty payments on the net sales of a product for these indications, ranging from a high single-digit to low double-digit percent.

17:01 EDT Moderna selects Amazon Web Services as preferred cloud provider - Amazon Web Services (AMZN) announced that Moderna (MRNA) has selected AWS as its preferred cloud provider, as well as its standard for analytics and machine learning workloads. Leveraging its mRNA platform and manufacturing facility with the AWS-powered research engine, Moderna delivered the first clinical batch of its vaccine candidate against COVID-19 to the NIH for the Phase 1 trial 42 days after the initial sequencing of the virus. By building and scaling its operations on the world's leading cloud, Moderna is able to quickly design research experiments and uncover new insights, automate its laboratory and manufacturing processes to enhance its drug discovery pipeline, and more easily comply with applicable laws and regulations during production and testing of vaccine and therapeutic candidates.

17:00 EDT KB Home says gross orders increased 14% y/y in June and July - KB Home announced that for the months of June and July 2020 its gross orders collectively increased 14% year over year to 3,275, and net orders grew 17% to 2,682. The cancellation rate for the period improved to 18%, from 20% in the year-earlier period. The Company's net order growth reflected year-over-year increases of 11% in June and 23% in July. The update was provided in advance of virtual meetings between management and investors at the Barclays Select Series: Building & Building Products event on August 6, 2020. "We experienced an acceleration in net order growth through the first two months of our 2020 third quarter, with an exceptionally strong monthly absorption rate per community of 5.5, up 22% year over year," said Jeffrey Mezger, Chairman, President and Chief Executive Officer. "We believe our affordably priced products in desirable locations and our Built-to-Order model, which provides personalization and choice, are the key drivers of our healthy sales pace, together with historically low mortgage interest rates and an increase in housing demand. While all of our communities are open to walk-in traffic, following appropriate safety protocols and applicable public health guidelines, homebuyers have options in how they engage with us, as we have reimagined our online homebuying experience with a broad range of enhanced tools, including virtual home tours, interactive floor plans, live chats with our sales counselors and online consultations in our Design Studios, underscoring our robust virtual selling capability."

16:56 EDT Enviva Partners raises quarterly distribution to 76.5c per unit - Enviva Partners declared a distribution of $0.765 per common unit for the second quarter of 2020. This distribution represents the twentieth consecutive distribution increase since the Partnership's initial public offering. The Partnership's distributable cash flow, net of amounts attributable to incentive distribution rights paid to our general partner, of $18.4 million for the second quarter of 2020 covers the distribution for the quarter at 0.61 times. The quarterly distribution will be paid on Friday, August 28, 2020, to unitholders of record as of the close of business on Monday, August 17, 2020.

16:54 EDT Parsley Energy narrows 2020 capital budget to less than $650M-$700M

16:51 EDT CommScope announces passing of CCO Jeff White - CommScope issued the following statement: "It is with great sadness that we announce the sudden passing of our Chief Commercial Officer Jeff White. On behalf of our Board of Directors, our leadership team and our employees around the world, we extend our sympathies to Jeff's family and friends." CommScope Chief Executive Officer Eddie Edwards said, "Although new to CommScope, Jeff made an immediate impact on our team, bringing his expertise and talents to our sales and marketing teams, positioning them for success during an extremely challenging period." Jeff White joined CommScope in May 2020. Before CommScope, Jeff served in leadership roles for Here Technologies, Syniverse, Extreme Networks, and Cisco.

16:46 EDT Earthstone Energy expects to average 13,000 - 14,000 Boepd for full year - Robert Anderson, President and CEO of Earthstone, said, "We executed our voluntary shut-in / curtailment program successfully in the second quarter without production complications or additional expense. Our continued focus on operating expense reduction was evident during the quarter as expenses were reduced by 40% compared to the first quarter, which was partially driven by shut-ins during May. All of our wells have been returned to full production and based on our recently announced updated production guidance, we expect to average 13,000 - 14,000 Boepd for the full year and therefore have relatively flat production from 2019 to 2020 with our previously guided capital expenditures of $50-60 million. With the vast majority of our capital program for 2020 completed in the first half of the year, we now have 11 wells drilled but uncompleted. Depending on completion timing, these 11 wells should allow us to maintain production relatively flat in 2021 with net capital expenditures presently estimated at $30 million. For the remainder of 2020 we will continue to focus on cost control and generating Free Cash Flow while considering various consolidation opportunities that are a direct result of the current environment."

16:44 EDT CoreCivic to revoke REIT election, discontinue quarterly dividend - CoreCivic announced that its board has unanimously approved a plan to revoke its Real Estate Investment Trust, or REIT, election and become a taxable C corporation, effective January 1, 2021. The decision is the result of an evaluation of corporate structure and capital allocation alternatives announced on June 17, 2020. The company will continue to operate as a REIT for the remainder of the 2020 tax year, and existing REIT requirements and limitations, including those established by the company's organizational documents, will remain in place until January 1, 2021. Additionally, the board voted unanimously to discontinue the company's quarterly dividend and prioritize allocating the company's substantial free cash flow to debt reduction, with a target total leverage ratio of 2.25x to 2.75x, excluding project specific non-recourse debt.

16:42 EDT 21Vianet appoints Tim Chen as Chief Strategy Officer - 21Vianet Group announced that Tim Chen will join the company as its Chief Strategy Officer in August. Prior to joining 21Vianet, Chen spent 14 years in investment banking and private equity firms, including eight years at Morgan Stanley and four years at J.P. Morgan, followed by over a decade at a private logistics company as its CFO.

16:40 EDT Lincoln National reports book value per share up 17% from prior year to $107.28 - As of June 30, 2020, book value per share, including AOCI, increased 17% from the prior-year period to $107.28. Book value per share, excluding AOCI, decreased 1% from the prior-year period to $69.38.

16:39 EDT Hillenbrand reports order backlog up 20% y/y to $1.12B

16:37 EDT Costco reports July total comparable sales up 13.2%, up 15.8% excluding fuel - Costco Wholesale Corporation reported net sales of $13.04B for the retail month of July, the four weeks ended August 2, an increase of 14.1% from $11.43B last year. For the forty-eight weeks ended August 2, the company reported net sales of $149.66B, an increase of 8.8% from $137.56B during the similar period last year.

16:32 EDT Surmodics receives FDA clearance for Sublime Radial Access 0.014 RX PTA Catheter - Surmodics announced it has received FDA 510 clearance for its Sublime Radial Access 0.014 Rapid Exchange, or RX, Percutaneous Transluminal Angioplasty, or PTA, Dilatation Catheter. The Sublime Radial Access 0.014 RX PTA Catheter allows below-the-knee access through a transradial approach by providing the longest working length on the market. Outer balloon diameters range from 2.0 mm to 4.0 mm with balloon lengths between 20 mm and 220 mm. The product joins the previously cleared Sublime Radial Guide Sheath within the company's Sublime Radial Access Platform and is designed to facilitate radial access for the treatment of above- or below-the-knee arteries.

16:25 EDT Allied Motion board approves quarterly cash dividend of 3c per share

16:21 EDT Anika Therapeutics appoints Michael Levitz as CFO - Anika Therapeutics announced the appointment of Michael Levitz as executive VP, CFO and Treasurer, starting August 10. Levitz brings over 20 years of public company financial experience to Anika. He succeeds Sylvia Cheung, who will continue with the company in an advisory capacity for a period following the succession effective date to assist with a smooth transition.

16:16 EDT Anavex receives TGA special access scheme approval for ANAVEX 2-73 - Anavex Life Sciences Corp. announced that patients from the ANAVEX 2-73-003 phase 2a Alzheimer's disease trial will continue treatment with ANAVEX 2-73 via the Australian Government Department of Health - Therapeutic Goods Administration, or TGA, compassionate use Special Access Scheme following completion of over 5-years daily dosing of ANAVEX 2-73 and recommendation by their physicians. The TGA approved the Special Access Scheme Category B applications based on the safety profile of ANAVEX 2-73, as well as clinical evidence that ANAVEX 2-73 may benefit patients. Anavex will facilitate continued access to ANAVEX 2-73 through the Special Access Scheme at the physicians' request.

16:15 EDT GoDaddy settles Tax Receivable Agreements for $850M payment - GoDaddy today announces that key parties to GoDaddy's Tax Receivable Agreements have agreed to settle the TRAs obligation in its entirety for a one-time, $850M payment. The agreement is expected to eliminate approximately $1B in cash tax-related payments through 2028 under the current tax regime. The transaction will be funded by a combination of cash on hand and new debt.

16:14 EDT e.l.f. Beauty announces new lifestyle beauty brand with Alicia Keys - e.l.f. Beauty announced the creation of a new lifestyle beauty brand with Alicia Keys. "A culmination of Keys' personal skincare journey and her passion for bringing light into the world, this new lifestyle beauty brand will enable Alicia to further explore conversations about inner beauty, wellness and connection. With an inclusive point of view, an authentic voice, and a line of skin-loving, dermatologist-developed, cruelty-free products, the brand aims to bring new meaning to beauty by honoring ritual in our daily life and practicing intention in every action. The brand is expected to launch in 2021," the company said.

16:11 EDT Caladrius CFO Joseph Talamo resigns - Caladrius Biosciences announced that Joseph Talamo, CFO, has tendered his resignation in order to explore opportunities outside of Caladrius. To ensure a smooth transition, Talamo plans to continue to serve as CFO until August 21. Caladrius has initiated a search to identify qualified candidates to fill the permanent CFO position and will provide an update in due course.

16:08 EDT Roku says Steve Louden to remain CFO - Roku said that Steve Louden will be staying as Roku's CFO and that the company has ended the search for his successor. . "Steve has deep knowledge of the business and has helped Roku navigate a fast-moving industry environment," said Anthony Wood. "I'm very pleased that Steve will be continuing in this leadership role at Roku at such an important time." Steve Louden added: "Roku is an exceptional company with a strong performance culture and we've only just begun to see the full transition to streaming."

16:04 EDT SAFR from RealNetworks awarded $1.9M in SBIR contracts - SAFR from RealNetworks announced it has been awarded two Phase II Small Business Innovation Research contracts of approximately $950K each or $1.9M in total from AFWERX. These contracts provide funding to adapt the SAFR platform for use by the Air Force for perimeter security and secure access. Once developed for the USAF, the SBIR/STTR program allows for any other federal agency to award a sole-source contract for technology developed under the program.

15:49 EDT Becton Dickinson recall identified as Class I by FDA - CME America is updating their previously announced recall from April 27 because the BodyGuard Infusion System Administration Sets may have a slower than expected delivery of medication, faster than expected delivery of medication, or a delay in therapy, the FDA announced. "The reason for the infusion errors is not known. The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death," the FDA's recall notice stated. Reference Link

15:07 EDT Audi e-tron SUV offered at $65,000 starting MSRP, $9,000 lower than 2019 model - Audi said in a statement that, "The 2021 Audi e-tron SUV family receives an impressive host of updates and a new, compelling price point for the 2021 model year. The fully electric Audi models offer refined SUV designs, with everyday utility and distinctive road presence. The Audi e-tron and e-tron Sportback are the first and second fully electric vehicles in the Audi lineup, laddering up to the brand's commitment to 30% of the U.S. model lineup being fully or partially electrified by 2025. New for model year 2021, the Audi e-tron model lines receive impressive revised packaging, including attractive entry pricing with a new Premium trim level. As a result, the e-tron SUV is offered at $65,900 starting MSRP for the model year 2021, a decrease of close to $9,000 from the starting MSRP of the model year 2019 Premium Plus e-tron. The e-tron lineup also receives a number of technical spec enhancements for improved utility. Through optimized drive system hardware and software adjustments, the 2021 e-tron achieves efficiency improvements resulting in an EPA-estimated range of 222 miles, an increase of 18 miles. Meanwhile, the e-tron Sportback delivers an EPA-estimated range of 218 miles. As technology progresses, the e-tron lineup has seen its most significant improvements with available battery capacity and efficiency. For a more efficient configuration, thanks to a number of optimizations, the front electric motor is able to be entirely disengaged, dramatically reducing power usage when not needed. Only when the driver demands more power or traction do both motors spring into action, providing the surefootedness of Audi quattro technology and the powerful dynamics Audi is known for. In addition, the usable amount of the high-voltage battery has increased for the model year 2021 e-tron lineup. The battery in the Audi e-tron and e-tron Sportback have a total capacity of 95 kWh and now gives customers access to a net energy figure of 86.5 kWh- almost 3 kWh more than 2019 e-tron model. The energy buffer is designed to help ensure customers enjoy sustained battery performance throughout the life of the vehicle. Enhancing the charging experience are dual charge ports on the driver and passenger side of the vehicles, newly available on the Premium Plus trims of the e-tron and e-tron Sportback."Reference Link

14:47 EDT DoorDash introduces DashMart, 'a new type of convenience store' - Andrew Ladd, Director, New Verticals for DoorDash said in a blog posting: "For years, people have used the DoorDash platform to access the best in their communities. During these trying times, our platform has become a critical lifeline to those we serve, and we've been hyperfocused on building new products that meet the immediate needs of our customers while helping our merchant partners thrive in new ways. For our customers, we've accelerated our efforts to bring household essentials to their doors. In April, we launched the Convenience category on DoorDash, powered by partnerships with 7-Eleven, Walgreens (WBA), CVS (CVS), Wawa, and more. Now our Convenience category includes more than 2,500 convenience shops across more than 1,100 cities nationwide...In support of both of these efforts, today we're announcing the launch of DashMart stores nationwide. DashMart is a new type of convenience store, offering both household essentials and local restaurant favorites to our customers' doorsteps. On DashMart, you'll find thousands of convenience, grocery, and restaurant items, from ice cream and chips, to cough medicine and dog food, to spice rubs and packaged desserts from the local restaurants you love on DoorDash. DashMart stores are owned, operated, and curated by DoorDash."Other companies in varying sectors may be interested in this include Rite Aid (RAD), Amazon (AMZN), Walmart (WMT), Target (TGT) Uber (UBER) and GrubHub (GRUB). Reference Link

14:17 EDT Novartis granted orphan status for hemoglobinuria treatment - The FDA granted Novartis orphan status for its treatment of paroxysmal nocturnal hemoglobinuria. Reference Link

13:48 EDT TikTok updates Community Guidelines to build safe shared global space - In an earlier blog posting, TikTok said: "TikTok's mission is to inspire creativity and bring joy. We are building a global community where users can create and share authentically, discover the world around them, and connect with others across the globe. We are also committed to keeping this community safe. Our Community Guidelines reflect our values and define a common code of conduct on our platform...These guidelines also allow our community to help maintain a safe shared space. Our values form the foundation of our Community Guidelines. We remove content including video, audio, image, and text that violates our Community Guidelines, and suspend or ban accounts involved in severe or repeated violations. Under certain circumstances, we will go one step further and report the accounts to relevant legal authorities to keep our community safe...Our Community Guidelines apply to everyone, and to everything shared on TikTok. They provide general guidance on what is and what is not allowed on the platform. We also recognize that some content that would normally be removed per our guidelines could have value to the public. Therefore, we may allow exceptions under certain circumstances...We update our Community Guidelines from time to time to evolve with community behavior, mitigate emerging risks, and keep TikTok a safe place for creativity and joy." Other companies in the social media space include Facebook (FB), Twitter (TWTR), Snap (SNAP). According to media sources, Microsoft (MSFT) is in the process of acquiring TikTok. Reference Link

12:32 EDT Rite Aid appoints Paul Gilbert general counsel, corporate secretary - Rite Aid has named Paul Gilbert as its general counsel and corporate secretary. Since joining Rite Aid on an interim basis earlier this year, Gilbert has played a key role in the company's efforts to evolve into a destination for whole being health. As general counsel, he will serve on Rite Aid's Executive Leadership Team and Senior Leadership Team, and will assume leadership over the organization's legal efforts. Gilbert joined Rite Aid in an interim role on May 21, to assist with the company's virtual annual meeting of stockholders, and other governance matters.

12:14 EDT Sempra Energy board approves repurchase of added $2B of shares - Along with its earnings report, Sempra Energy said: "As part of Sempra Energy's goal of returning additional value to shareholders, the company recently completed a $500 million share buyback program. It also received authorization from its Board of Directors to repurchase an additional $2 billion of shares at future dates. Sempra Energy's capital allocation strategy has enabled the company to return approximately $13 billion to common shareholders since 2000 through cash dividends and common share repurchases."

12:07 EDT Genfit announces publication of NIS4 technology in Lancet - Genfit earlier today announced that pivotal data describing the derivation and validation of NIS4 has been accepted for publication by The Lancet Gastroenterology & Hepatology. NIS4 is the company's non-invasive, blood-based diagnostic technology, developed to identify patients with nonalcoholic steatohepatitis and significant to advanced fibrosis. Suneil Hosmane, Head of Global Diagnostics at Genfit commented: "This publication represents a milestone achievement for our NIS4(TM) technology. The data presented in The Lancet Gastroenterology and Hepatology showcases not only the robust and consistent performance of NIS4 to identify at-risk NASH, but also the improved performance of NIS4 relative to other technologies including commonly used liver fibrosis tests." Genfit intends to license NIS4 technology to a diagnostic partner to enable the development and projected launch of a clinical diagnostic test powered by NIS4 in the second half of 2020. Genfit added that it continues to explore opportunities to obtain formal marketing authorization of an in vitro diagnostic version of NIS4 in both the U.S. and European markets.

12:02 EDT IMAC reports FDA authorization to initiate study of stem cells in Parkinson's - IMAC Holdings announced the United States Food and Drug Administration approved its investigational new drug application, which IMAC submitted in May 2020, for the use of umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia, or the gradual loss and slowing down of spontaneous body movement, due to Parkinson's disease. The company will now initiate enrollment of 15 patients for its Phase 1 trial to evaluate the safety and tolerability of the stem cell product acquired from technology developed by a major research university to treat patients with Bradykinesia due to Parkinson's utilizing intravenous administration of Wharton's jelly-derived mesenchymal stem cells. "The company believes that the causes of bradykinesia may be related to an inflammatory response in the body. The company's new study is designed to confirm this belief and support the Company's long-term strategy for the use of regenerative medicine in combination with physical rehabilitation to reduce the effect of movement-restricting diseases," IMAC stated.

12:00 EDT New Relic falls -25.8% - New Relic is down -25.8%, or -$18.94 to $54.56.

12:00 EDT Modine Manufacturing rises 17.7% - Modine Manufacturing is up 17.7%, or $1.01 to $6.72.

12:00 EDT Team rises 29.1% - Team is up 29.1%, or $1.15 to $5.10.

10:30 EDT AgEagle Aerial Systems announces pricing of $10M stock and warrant offering - AgEagle Aerial Systems announced it has entered into a securities purchase agreement with an institutional investment firm, which is an existing AgEagle shareholder. The investor is purchasing 3,355,705 shares of common stock and warrants to purchase up to 2,516,778 shares of common stock at an exercise price of $3.30 per share, for gross proceeds of approximately $10M. The warrants are for a ten month term from the date of closing and are not exercisable until February 6, 2021. The company expects the net proceeds from the offering to be approximately $9.9M, which it expects to spend for general working capital and capital expenditure purposes. The offering is expected to close on or about August 6.

10:18 EDT Carnival joins industrywide cruising pause in U.S. through October 31 - Carnival Cruise Line (CCL) stated: "Consistent with the decision announced today by the members of the Cruise Lines International Association to voluntarily extend the pause in U.S. cruise embarkations until Oct. 31, 2020, Carnival Cruise Line has informed guests and travel advisors that we have cancelled all cruises scheduled to embark between Oct. 1 and Oct. 31. Guests are being offered an enhanced value package of a future cruise credit and onboard credit, or a full refund. If conditions in the U.S. change and short and modified sailings are possible, the industry may consider an earlier restart, and we would consider that as well. In the meantime, we will continue to work with public health and government officials to finalize enhanced health and sanitation protocols and procedures that will guide our eventual return to service." Earlier, Royal Caribbean (RCL) announced that it will be will be extending the suspension of sailings to include those departing on or before October 31, 2020, excluding sailings from China and Australia.

10:05 EDT Royal Caribbean extends suspension of cruising

10:00 EDT Teladoc falls -14.7% - Teladoc is down -14.7%, or -$36.62 to $212.80.

10:00 EDT Vapotherm falls -29.2% - Vapotherm is down -29.2%, or -$15.40 to $37.34.

10:00 EDT Team rises 18.2% - Team is up 18.2%, or 72c to $4.67.

09:57 EDT Nikola well off lows after chairman CNBC interview, shares still down 8%

09:56 EDT WeedMD signs licensing agreemet to produce Mary's Medicinals products - WeedMD announced it has entered into an exclusive licensing, manufacturing and distribution agreement with U.S.-based cannabis wellness house, MM Technology Holdings, owner of Mary's Brand and product line Mary's Medicinals. Under the terms of the Agreement, as Mary's sole Canadian partner, WeedMD will manufacture a suite of Mary's Medicinals' products in-house with its own input biomass at its state-of-the-art extraction hub CX Industries later this year. WeedMD will also market, sell and distribute Mary's Medicinals' products across Canada's provincial adult-use and direct-to-consumer medical channels as it looks to expand new cannabis offerings to address an underserved wellness and medical market segment. Widely recognized for its innovative portfolio of delivery methods, Mary's suite of cannabis products includes transdermal gels and patches and topicals.

09:52 EDT Nikola spent $11M less than expected in Q2 and built Badget, Milton says - Trevor Milton, Nikola founder and executive chairman, is speaking on CNBC.

09:49 EDT Nikola now requires deposit for every reservation, chairman says - Trevor Milton, Nikola founder and executive chairman, is speaking on CNBC.

09:47 EDT Nikola has five zero-emission trucks built in German, chairman says - Trevor Milton, Nikola founder and executive chairman, is speaking on CNBC.

09:47 EDT New Relic falls -23.7% - New Relic is down -23.7%, or -$17.39 to $56.10.

09:47 EDT Square rises 14.2% - Square is up 14.2%, or $19.46 to $156.29.

09:47 EDT Boot Barn rises 16.6% - Boot Barn is up 16.6%, or $3.38 to $23.70.

09:45 EDT Nikola chairman has three manufacturer term sheets for Badger deal - Trevor Milton, Nikola founder and executive chairman, is speaking on CNBC.

09:39 EDT Buffett's Berkshire Hathaway adds to Bank of America position - Bank of America (BAC) holder Berkshire Hathaway (BRK.A, BRK.B) disclosed in a regulatory filing last night that it had purchased 13,584,301 shares of the bank's stock at an average price of $24.81 per share between July 31 and August 4. The total transaction value of the purchase made by Warren Buffett's firm was $337,061,827.

09:28 EDT Corbus completes enrollment in DETERMINE Phase 3 study of lenabasum - Corbus Pharmaceuticals announced the completion of subject enrollment in DETERMINE, a Phase 3 study assessing the efficacy and safety of lenabasum for the treatment of dermatomyositis. The Company expects to report topline results from this study in the fourth quarter of 2021. The Company's Phase 3 DETERMINE study has enrolled 176 subjects in the largest, randomized, double-blind, placebo-controlled DM study to date. This study is being conducted in North America, Europe, and Asia. Patients in the study are randomized 2:1:2 to either receive lenabasum 20 mg twice per day, lenabasum 5 mg twice per day or placebo twice per day for 52 weeks with a follow-up period of 4 weeks. The primary endpoint of DETERMINE is efficacy of lenabasum compared to placebo as measured by the American College of Rheumatology/ European League Against Rheumatism 2016 Total Improvement Score in myositis at 52 weeks, a weighted composite measure of improvement from baseline in six core set items that include physician directed assessments of Physician Global Activity, Manual Muscle Testing-8, and Extramuscular Global Activity, patient-reported outcomes of Patient Global Activity and Health Assessment Questionnaire, and biomarkers of muscle enzymes. Multiple secondary outcomes including Cutaneous Dermatomyositis Activity and Severity Index activity score are being evaluated. Additionally, the Company is evaluating the safety and efficacy of lenabasum in an open-label extension of the DETERMINE Phase 3 study. The open-label extension enables participants who complete the double-blind study period to continue to receive lenabasum. Lenabasum was granted Orphan Drug Designation for the treatment of dermatomyositis from the U.S. Food and Drug Administration and the European Medicines Agency.

09:22 EDT O2Micro names Gregory FCA as investor relations advisor - O2Micro announced it has engaged Gregory FCA to assist with its investor relations program.

09:21 EDT Walmart announces Walmart Drive-in movie theaters in parking lots - Walmart said in a release, "Walmart is lifting the curtain on plans for the Walmart Drive-in, a drive-in movie theater experience, which is rolling into 160 Walmart stores across the country beginning this month, created in partnership with the Tribeca Film Festival. Available for free to Walmart customers, the Walmart Drive-in will transform Walmart parking lots into outdoor cinemas from August 14 through October 21 with 320 showings of hit movies. During the tour, filmmakers and special guests will help Walmart celebrate bringing back the big screen to communities across the country. Drew Barrymore will serve as virtual host for all events, welcoming guests to a fun family night experience. She will also make a surprise in-person appearance at one location. Families will be also be treated to surprise virtual or in-person appearances from Peter Berg, Jennifer Garner, LeBron James and Chrissy Metz at select showings."

09:19 EDT Alkaline Water's A88CBD to launch in Elevated Wellness CBD - The Alkaline Water Company announces that A88CBD's complete portfolio of CBD topicals and ingestibles products will be available in Elevated Wellness' retail locations and its e-commerce store. Founded by healthcare professionals, Elevated Wellness is an Austin, Texas-based CBD company that exclusively carries hemp-based products that are grown in the United States and hold gluten-free and vegan certifications.

09:16 EDT Net 1 UEPS CEO Herman Kotze to step down at end of September - Net 1 UEPS Technologies announced that, after 22 years with the Company, Mr. Herman Kotze will be stepping down on September 30, 2020, as the CEO and director of the financial technology multinational. Mr. Alex Smith, Net1's CFO, will take over as the interim CEO upon Mr. Kotze's departure, until the board finalizes the appointment of a permanent CEO. To ensure a steady transition, Mr. Kotze has agreed to provide consulting services to the Company through May 31, 2021. Net1 expects to release its financial results for the year ended June 30, 2020 in September 2020. At that time, the Company will provide an update on its strategic direction, which will be focused on growing the core South African operations and optimizing capital allocation.

09:12 EDT ShiftPixy Labs to support rise of ghost kitchens - ShiftPixy added additional commentary around last week's launch of ShiftPixy Labs, a new suite of marketing and support services for quick service restaurant operators. The COVID-19 pandemic has proven a game-changer for QSRs, which are now embracing ghost kitchens in response to social distancing mandates. New ghost kitchens have already raised more than $500 million in capital and are spreading quickly nationwide. Euromonitor expects a $1 trillion market globally by 2030, which could replace up to half of all dine-in volume as early as 2022. ShiftPixy aims to provide sophisticated technology to assist with all aspects of establishing and operating a successful ghost kitchen, and with the launch of ShiftPixy Labs last week, is inviting budding and established restaurant entrepreneurs alike to partner with ShiftPixy to drive their future success.

09:11 EDT Nano Dimension president, CEO Yoav Stern invests in company - Nano Dimension announced that Yoav Stern, who joined the Company as President and CEO in January 2020, is purchasing from the Company a Series A warrant to buy up to 6,880,402 of the Company's ADSs for an aggregate exercise price of $5,160,302. The cost of the warrant is $150,000. The warrant will vest over a period of two and a half years and will have a term of seven years. Simultaneously with his investment, Mr. Stern is forfeiting options to purchase 29,050,000 Ordinary Shares of the Company, previously granted to him under the Nano Dimension Ltd. Employee Stock Option Plan. In a statement to the Company's shareholders, Mr. Stern commented: "My investment was proposed by me six months ago when I joined the Company, but regulatory circumstances requested shareholders' approval, which was granted on July 7, 2020. It is important for me to align my interests with my partners, the shareholders of Nano Dimension, by becoming an investor like them. In addition, it is as important to me to demonstrate my commitment to our devoted employees and forfeit all of my stock options so that they will be available for allocation to present and future teams, rather than myself. Suffice it to say, that the structure of my investment, which limits me from selling its entirety for at least two and a half years, is an indication of my conviction in the tremendous mid-and-long term upside in the value of the Company. The a posteriori question stemming from the suffix of the statement above relates to business prognosis for the short term. As I have stated in our last conference call on May 14, 2020, the revenue for Q2-2020 is expected to be close to zero. The Covid-19 effects are specifically cardinal as they relate to abrupt "hold-backs" on capital expenses. This is true even for our prospects and customers that slowly start to operate again. In my foray into an M&A search, with active help of Needham and Co., I can assure you that these phenomena are shared by the vast majority of the companies which I have inspected, out of approximately 50 companies that we have researched over the last 45 days. This is the bad news. The good news is that contrary to most others in the 3D-printed electronic industry, and thanks to your support, we are positioned in the best possible way with enough cash that enables flexibility. We have made a decision in Nano Dimension: If millions of dollars will be spent on go-to-market and sales and marketing to increase revenue dramatically in the short term, it will be a waste of time and money. The temporary-yet-prolonged effects of the corona pandemic is a fact, and the will of understandably confused and/or careful customers to invest in breakthrough, new prototyping and fabrication technologies of unique PCBs is dramatically hampered. We at Nano Dimension, cannot stop the tsunami. But we have enough air to dive under it and emerge in the mid-term as even clearer winners. Potentially, maybe with a few other, "last men standing" effect...I believe Nano Dimension will emerge out of the Covid-19 saga with a reinforced competitive market position and hence, growth potential will possibly manifest itself faster than expected."

09:07 EDT Customers Bank appoints Eric Holmquist as Chief Risk Officer - Customers Bank announced Eric Holmquist joined the institution as Executive Vice President and Chief Risk Officer. Most recently, Holmquist served as managing principal, enterprise risk management at Capco.

09:05 EDT Comtech awarded $20M additional funding from U.S. Army - Comtech Telecommunications announced that during Q4, its Mission-Critical Technologies group, which is part of Comtech's Government Solutions segment, was awarded $20 million of additional funding on a previously announced $223.4 million contract to provide Very Small Aperture Terminals to support the U.S. Army. The contract has been funded $214.9 million to date.

09:03 EDT Infrastructure and Energy Alternatives awarded $77M solar contract in Texas - Infrastructure and Energy Alternatives announced that the Company has begun construction on a solar farm in Texas. The $77M engineering, procurement and construction contract was awarded to IEA Constructors, a subsidiary of IEA that manages utility-scale energy and heavy civil infrastructure projects. Construction of the Texas photovoltaic farm is underway and is expected to be completed in June 2021. IEA will self-perform all of the civil, mechanical and electrical work at the project site. Texas has quickly become a leader in solar production. Ranked fifth in the nation for total solar capacity installed and fourth for the largest number of solar jobs, nearly $6.5B in solar funding has been invested into Texas to date. According to the Solar Energy Industries Association, an additional four gigawatts of solar capacity is expected to be installed in Texas over the next five years.

09:02 EDT Revive finalizing agreements to initiate Phase 3 trial of bucillamine - Revive Therapeutics announced that following the U.S. Food & Drug Administration approval to proceed with the Company's Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19, the Company is finalizing agreements and aligning resources to initiate the Phase 3 clinical trial in September. Revive expects to engage up to 10 clinical trial sites in the U.S. and open the Phase 3 clinical trial for patient screening in Q3-2020. The Company is finalizing vendor agreements in the project management, medical monitoring, data management and clinical packaging for the trials. In addition, Revive and its clinical trial partners will be evaluating potential U.S. clinical sites and clinical investigators in major COVID-19 affected U.S. states, such as Florida, California, Arizona and Texas.

08:49 EDT Verizon Ventures leads EUR4M Series A financing round in PICadvanced - Verizon Ventures announced it led a EUR4M Series A financing round in PICadvanced, a developer of cost-effective optics and photonics solutions for telecom applications. Joining Verizon Ventures in the round is a 200M Co-investment Fund managed by PME Investimentos, which makes co-investments in high-growth Portuguese startups. Founded in 2014 and based in Ilhavo, Portugal, PICa has been active in the development of optoelectronic transceivers for a new telecommunications network standard called NG-PON2. Leveraging its expertise, the company aims to provide innovative solutions for the Passive Optical Network market. It has solved many complex problems through optics, from design and development to packaging and testing that are used in the electrotechnology, telecommunications, and biomedicine industries. NG-PON2's advantage is said to increase the capacity of the network and deliver more bandwidth at a lower cost per bit. PICa is also pioneering the design of Photonic Integrated Circuits, which will significantly reduce the cost of producing optical modules and break most of the bottleneck created by conventional optic devices.

08:47 EDT iFresh joins United Nations Global Compact - iFresh announced that it has been accepted into the United Nations Global Compact. iFresh's participation in the United Nations Global Compact is part of the Company's commitment to developing a sustainable business while achieving long-term success in the grocery retail industry. The United Nations Global Compact is a global network of over 9,500 companies and 3,000 non-business signatories dedicated to building a sustainable future. As the world's largest corporate sustainability initiative, the United Nations Global Compact is leading worldwide transformation by challenging and enabling the organizations to take more ambitious action on sustainable development goals.

08:44 EDT Barfresh Food Group launches WHIRLZ juice concentrates - Barfresh Food Group announced the launch of its new WHIRLZ 100% Juice Concentrates. The new 5:1 juice concentrates will initially target elementary and secondary schools and are a perfect complement to the company's current existing 1:1 bulk Easy Pour products used in beverage dispensing equipment. The 100% juice concentrates offer a more affordably priced product that responds to the need of the schools to have a wider range of options at various price points. Barfresh plans to include the new product as part of its product offerings to customers in the education channel once schools re-open this upcoming school year. This new product range is stored and delivered ambient, which opens many more opportunities for the company as it works on strategic distribution partnerships to help accelerate sales within the education channel.

08:43 EDT ASRT approves Sensus Healthcare's SRT systems for continuing education units - Sensus Healthcare reports that the American Society of Radiologic Technologists has approved Sensus Healthcare's SRT Systems for Continuing Education Units. The approval covers all three SRT systems offered by Sensus, namely the SRT-100(TM), the SRT-100+ and the SRT-100 Vision, and automatically recognizes Sensus Healthcare training as a legitimate provider for CEUs. The ASRT approval provides radiation therapists Category A credits, with 4.5 CEUs for the SRT-100 and SRT 100+, and 6.5 CEUs for the SRT-100 Vision in-person clinical trainings beginning September 1, 2020. Now that the ASRT has recognized the Company's training with CEUs, the American Registry of Radiologic Technologists automatically recognizes Sensus Healthcare training as a legitimate provider for CEUs. The ARRT requires Registered Technologists to complete and report 24 credits of approved continuing education activities every two years to maintain their registration.

08:41 EDT JetBlue no longer allowing customers to claim exemptions for face coverings - JetBlue said in a release, "JetBlue was the first airline to require customers to wear a face covering during the entire travel journey, including at the airport. In line with information from the Centers for Disease Control and JetBlue's own medical experts, starting August 10, the airline will no longer allow the use of face masks with vents or exhalation valves. JetBlue will also no longer allow customers to claim exemptions from wearing a face covering altogether. 'The simple act of wearing a proper face covering is one way we can all help ensure the safety of all JetBlue crewmembers and customers,' COO Joanna Geraghty said. 'Our terminals and airplanes are a shared space, and every customer must wear a proper face covering or will need to delay their travel on JetBlue until face coverings are no longer required. Our policy is meant to offer the strongest level of protection for everyone given all that we currently know about how COVID-19 is transmitted.' An acceptable face covering or mask must cover a customer's nose and mouth and is required to board all JetBlue flights. If a crewmember identifies a face covering or mask that does not appear sufficient based on its features or potential lack of protection, they will provide a mask for the customer to use instead. Customers two years and younger will not be required to wear a face covering if they cannot maintain one. Customers who do not agree to wear a face covering will not be allowed to board any aircraft, and customers who do not follow crewmember requests to wear a face covering while in flight will be reviewed for future travel on JetBlue."

08:39 EDT Yield10 Bioscience announces spring planting of Camelina - Yield10 Bioscience announced that it established 50 acres of spring Camelina under contract with a grower in Montana in the second quarter of 2020. This is a business development activity necessary to gain experience in establishing the value chain for producing Camelina sativa seed at large scale as a source of new crop products. The objective of this activity was to gain experience in seed bulk-up, grower contracts, logistics and handling of harvested seed, including toll crushing, and to produce quantities of oil and protein meal for customer sampling. The crop has reached maturity and is currently drying down with harvesting expected in the weeks ahead.

08:38 EDT Myovant announces further financing from Sumitomo, collaboration with Sunovion - Myovant Sciences announced a $200 million low-interest, five-year term loan commitment from Sumitomo Dainippon Pharma Co, bringing its total financing support for Myovant to $600M, further bolstering Myovant's cash and committed funding and increasing the company's financing flexibility as it prepares for multiple potential product launches to treat advanced prostate cancer, uterine fibroids, and endometriosis. Additionally, Myovant announced that it has entered into a three-year commercial collaboration agreement with Sunovion Pharmaceuticals, an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma, for services to support the planned commercialization of investigational drug candidate relugolix. Under the agreement, Sunovion will provide third-party logistics, trade and retail distribution, contract operations, and market access account management services to Myovant and will become a non-exclusive distributor of relugolix for prostate cancer and the exclusive distributor of relugolix combination tablet for uterine fibroids and endometriosis in the U.S. The terms of the new loan facility are expected to be largely consistent with the initial $400 million low-interest, five-year term loan facility from Sumitomo Dainippon Pharma that was announced in December 2019, and does not provide Sumitomo Dainippon Pharma with any rights to relugolix. Myovant will be able to access the facility on a quarterly basis, subject to certain terms and conditions, with no repayments due until the end of the term subject to certain exceptions. The additional funds will be used to fund Myovant's operating expenditures, including preparation for the commercialization of relugolix.

08:36 EDT JetBlue continues commitment to blocking middle seats, travel flexibility in Oct - JetBlue announced several updates to its Safety from the Ground Up program, a multi-layered commitment to the safety of its crewmembers and customers. JetBlue is extending its commitment to seat distancing for flights through at least October 15 by blocking middle seats in rows where parties are not traveling together. JetBlue is also extending its Go Back and Forth with Confidence initiative through October 15, which provides travel flexibility by waiving change and cancellation fees for new bookings. Finally, JetBlue is strengthening its face covering policy to prohibit masks with vents or exhalation valves, and will no longer allow customers to claim exemptions from wearing a face covering altogether.

08:35 EDT WWE appoints Nick Khan as Chief Revenue Officer - WWE announced that Nick Khan, former Co-Head of Television at Creative Artists Agency, has been named President & Chief Revenue Officer, reporting directly to WWE Chairman & CEO Vince McMahon.

08:32 EDT Johnson & Johnson announces pact with U.S. for 100M doses of COVID-19 vaccine - Johnson & Johnson announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100M doses of Janssen's SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. FDA. The Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, in collaboration with the U.S. Department of Defense, is committing over $1B for this agreement. The vaccine will be provided at a global not-for-profit basis for emergency pandemic use. The U.S. government may also purchase an additional 200 million doses of Ad26.COV2.S under a subsequent agreement. The company is evaluating one- and two-dose regimens, in its clinical program and working diligently to ensure broad, global access to the vaccine following approval or authorization by regulators. Johnson & Johnson aims to meet its goal to supply more than one billion doses globally through the course of 2021, provided the vaccine is safe and effective.

08:28 EDT Calix promotes Michael Weening as COO - Calix announced Michael Weening's promotion to EVP and COO. In his new role, Michael adds Revenue EDGE solutions to his existing responsibilities leading sales, marketing, services, customer success and product operations.

08:21 EDT Wayfair expects to produce positive adj. EBITDA margins on a go-forward basis - Comments taken from Q2 earnings conference call.

08:18 EDT CVS Health says COVID-19 driving company to bend innovation curve - Says well-positioned to provide COVID-19 vaccines when available. Says continues to expand virtual care offerings. Says continues to make "significant progress" on strategic priorities. Comments from Q2 earnings conference call.

08:16 EDT Genpact, Deloitte form strategic alliance - Genpact and Deloitte announced a strategic alliance to offer comprehensive solutions to help organizations scale and optimize critical business operations, drive speed to outcome, deliver business transformation to enhance competitive growth, and build resilience in an uncertain future.

08:15 EDT Wayfair onboarding 1,000 new members to service team

08:14 EDT Clovis enrolls first patient in Phase 2 portion of LIO-1 trial - Clovis Oncology (CLVS) announced treatment of the first patient in the Phase 2 portion of the LIO-1 trial evaluating the combination of lucitanib, Clovis' investigational angiogenesis inhibitor, including vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), and Opdivo, Bristol Myers Squibb's PD-1 inhibitor, for the treatment of gynecologic cancers. The LIO-1 trial is sponsored by Clovis as part of its broad clinical collaboration with Bristol Myers Squibb (BMY). Clovis said in a release, "The Phase 2 part of LIO-1 is an open-label study to evaluate the safety and efficacy of lucitanib and Opdivo in patients with advanced gynecological solid tumors, including a broad spectrum of ovarian and endometrial subtypes including clear cell disease and patients with cervical cancer. The primary endpoint is confirmed best overall response rate based on investigator assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The study will be conducted in the U.S. and Europe, in collaboration with the European Network for Gynaecological Oncological Trial groups for European study sites. The Phase 2 dosing regimen for the LIO-1 study is based on results from the recently completed Phase 1b dose-escalation portion of the LIO-1 study. Abstracts describing the initial results of the Phase 1b portion of the LIO-1 study, as well as a trials-in-progress description of the Phase 2 study design of LIO-1, have been accepted as ePosters at the European Society for Medical Oncology Virtual Congress 2020 in September."

08:13 EDT Thermo Fisher launches high-throughput automated testing system for COVID-19 - Thermo Fisher Scientific introduced a new highly automated, real-time PCR solution designed to analyze up to 6,000 samples in a single day to meet increasing global demand for COVID-19 testing. The high-throughput system enables laboratories to double or even triple their testing capacity to support global efforts to return communities back to work and school.

08:12 EDT DLH Holdings appoints Stephen Zelkowicz to board of directors - DLH Holdings Corp. (DLHC) announced the appointment of Stephen J. Zelkowicz to its board of directors, effective immediately, with an initial term expiring with the 2021 Annual Shareholder's Meeting. With this addition, there will be eight members on the Company's Board. Mr. Zelkowicz currently serves on the board of Summer Infant, Inc. (SUMR), where he is chair of the Governance and Nominating Committee and a member of the Compensation Committee.

08:11 EDT Oasis Midstream Partners sees 2020 CapEx $36M-$40M

08:09 EDT Blackstone to acquire Ancestry for $4.6B - Blackstone said in a release, "Blackstone announced that private equity funds managed by Blackstone have reached a definitive agreement to acquire Ancestry from Silver Lake, GIC, Spectrum Equity, Permira, and other equityholders for a total enterprise value of $4.7 billion. Current Ancestry investor GIC will continue to retain a significant minority stake in the company. This transaction represents the first control acquisition for Blackstone's eighth vintage of its flagship private equity vehicle. Ancestry is the global leader in digital family history services, operating in more than 30 countries with more than 3 million paying subscribers across its Ancestry online properties and more than $1 billion in annual revenue. The company harnesses the information found in family trees and historical records to help people gain a new level of understanding about their lives. Ancestry also operates a market-leading consumer genomics business, which informs consumers about their heritage and key health characteristics."

08:07 EDT DXC Technology awarded multi-year agreement by Sabre - DXC Technology (DXC) announced that it has been awarded a multi-year agreement by Sabre (SABR). DXC said in a release, "DXC will partner with Sabre on its transformational journey to redefine the future of travel, helping to ensure the continued security, stability and health of Sabre's technology. DXC will help Sabre accelerate its transformation journey to meet the evolving demands of its airline, hospitality and travel agency customers in more than 160 countries. DXC will provide Sabre with outsourcing and IT modernization capabilities to run and maintain its systems effectively and efficiently while migrating workloads to the cloud, modernizing its technology and unlocking value across Sabre's global business. Building on Sabre's long and deep history with DXC, the expanded multi-year agreement extends DXC's services that support Sabre's global reservation platform through secure, resilient and efficient IT outsourcing and infrastructure services. DXC will also provide critical security, cloud, applications, analytics and engineering capabilities."

08:07 EDT Origin Agritech regains Nasdaq listing compliance - Origin Agritech announced that it has received notice from Nasdaq stating that the company has regained compliance with Nasdaq listing requirements.

08:06 EDT Allena expects cash, cash equivalents to fund requirement beyond 2Q21 - Based on its current plans, Allena expects that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements beyond the second quarter of 2021.

08:05 EDT Peabody Energy sees 2020 CapEx $200M

08:04 EDT eBay, LendingPoint partner to provide seller financing - eBay is partnering with LendingPoint to launch a new program that will give eBay sellers in the U.S. access to funding to help grow and sustain their businesses. The program, eBay Seller Capital powered by LendingPoint, is compatible with payments managed by eBay and will unlock opportunities for individuals and businesses to obtain financing, providing eligible sellers with a fast, flexible and transparent funding experience. eBay sellers who work with LendingPoint in the pilot program can obtain quick decisions and access to installment loans. This program will be offered with flexible terms of up to 48 months to allow sellers to choose the best option for their specific budget needs, and lower repayment plans as part of the longer terms. LendingPoint will not charge origination fees or early payback fees. In the future, through this partnership, eBay and LendingPoint aim to expand their offering to provide eBay sellers with more tools to help run their businesses. eBay Seller Capital powered by LendingPoint is rolling out now as a pilot program with select sellers and will be available to all eligible sellers in the U.S. later this year. During the initial launch, eligible sellers may receive up to $25,000 in funding in as little as one business day.

08:02 EDT Alaska Air says all guests must wear face covering at all times - As part of continuing efforts to keep guests and employees safe, Alaska Airlines announced that all guests must wear a cloth mask or face covering at all times when at the airport or onboard Alaska aircraft. Effective Aug. 7, all Alaska guests age 2 and older will be required to wear a cloth mask or face covering over their nose and mouth - with no exceptions. If a guest is unwilling or unable to wear a mask for any reason while at the airport, they will not be permitted to travel. If a guest refuses to wear a mask after boarding their flight, they will be suspended from future travel.

08:02 EDT Cass Information Systems appoints Matt Schuckman as General Counsel - Cass Information Systems has recruited Matt Schuckman to fill the newly created position of general counsel. Schuckman will also serve Cass as corporate secretary. Schuckman joins Cass after a 20-year career as a commercial and transactional attorney with the St. Louis office of Armstrong Teasdale, LLP.

08:01 EDT Unisys selected by Nevada's Department of Public Safety for IT modernization - Unisys has been selected by the State of Nevada to support its Department of Public Safety, Records, Communications and Compliance Division with a long-term, multi-phase effort to modernize various systems that comprise the Nevada Criminal Justice Information System. The project aims to modernize both the way in which it handles information requests from criminal justice agencies and requests for background checks from the public. The majority of applications supporting NCJIS will be hosted and managed by Unisys in the Microsoft Azure Government Cloud.

08:00 EDT Allogene Therapeutics expects to submit IND for ALLO-605 in 2021 - The Company presented preclinical data on its internally developed TurboCAR technology platform at the American Society of Gene & Cell Therapy 23rd Annual Meeting in May. TurboCAR technology allows cytokine activation signaling to be engineered selectively into CAR T cells. TurboCAR has the potential to improve efficacy, overcome cell exhaustion, and reduce dosing requirements of AlloCAR T therapy. In 2021, an IND is expected to be submitted for the Company's first TurboCAR candidate, ALLO-605, an investigational BCMA-directed AlloCAR T therapy for MM.

07:59 EDT Allogene Therapeutics expects inital data from Phase 1 UNIVERSAL trial in Q4 - The ALLO-715 Phase 1 UNIVERSAL trial in patients with relapsed/refractory MM utilizes ALLO-647 as part of the lymphodepletion platform. The initial dose escalation portion of the UNIVERSAL trial using 39mg of ALLO-647 is now complete. The trial continues to enroll patients with initial data anticipated in Q4 2020.

07:57 EDT Allogene sees readout from Phase 1 study of ALLO-501 in late 2020, early 2021 - In May 2020 at the American Society of Clinical Oncology annual meeting, the Company presented initial data from its dose escalation Phase 1 ALPHA study of ALLO-501 in relapsed/refractory non-Hodgkin lymphoma . This study utilizes ALLO-647, the Company's anti-CD52 monoclonal antibody, as a part of its differentiated lymphodepletion regimen. The next readout from this trial is expected to be in late 2020 or early 2021.

07:52 EDT Medtronic announces U.S. launch of InterStim Micro - Medtronic announced that its recently FDA-approved InterStim Micro neurostimulator for sacral neuromodulation therapy is now available in the United States. Cleveland Clinic performed the first patient implant in the nation with the new device.

07:50 EDT Calibre Mining recommences blasting, mining at Jabali Underground mine - Calibre Mining announced that blasting and mining activities have recommenced at its Jabali underground mine, part of the Libertad complex. Russell Ball, Chief Executive Officer of Calibre, stated: "We appreciate the hard work and supportive engagement by the Ministry of Energy and Mines and the local community at Barrio Jabali to safely and amicably relocate households that were impacted by ground stability issues created by illegal artisanal mining. Notwithstanding the extended shut-down of Jabali, our 'hub-and-spoke' operating philosophy provided sufficient short-term flexibility to enable us to continue to deliver production in line with our original expectations for 2020. Jabali represents an important long-term source of high-grade ore for the Libertad mill and is a key focus of our expanded drilling program. We currently have three drill rigs completing infill and step-out drilling at Jabali, which as at December 31, 2019 hosted an inferred mineral resource of 1.24 million tonnes at an average grade of 7.87 g/t Au containing 315,000 ounces of gold. We see excellent potential to upgrade inferred to indicated resources while expanding the resource along strike and down plunge. Notwithstanding the phased restart of mining activities at Jabali through the balance of this quarter, we are maintaining our recently provided 2020 outlook."

07:45 EDT DraftKings at Casino Queen launches sports betting in Illinois - DraftKings announced the launch of the DraftKings at Casino Queen Sportsbook app and retail location in Illinois. Customers can download the sportsbook app and visit DraftKings at Casino Queen in East St. Louis to finish creating their account onsite, providing them with statewide mobile sports betting access.

07:42 EDT CVS Health sees 2H20 Retail/LTC gross margins in line with YTD results - Retail/LTC: Expects continued COVID-19 related operating expenses and to benefit from testing capabilities. Expects 2H20 gross margins to be in line with YTD results. PSS: Expects the business to deliver growth in 2H20 reflecting strong Specialty pharmacy performance and continued execution of company strategy. HCB: Expects utilization in 2H20 to remain at more normal levels. Expects membership to be affected by unemployment and loss of a large Public & Labor ASC customer effective 9/1. Expects increase in Medicaid membership. Comments taken from investor presentation slides for Q2 earnings conference call.

07:42 EDT Pacira announces publication of Phase 4 study of EXPAREL - Pacira BioSciences announced that full results its Phase 4 study of EXPAREL administered via transversus abdominis plane field block in patients undergoing Cesarean section have been published in Anesthesia and Analgesia. In this study, EXPAREL achieved its primary endpoint with a statistically significant reduction in total postsurgical opioid consumption through 72 hours. EXPAREL also achieved statistical significance for reduction in percentage of opioid-spared patients through 72 hours. This was a multicenter, randomized, double-blind study across 13 clinical sites in the United States, in patients undergoing elective C-section and receiving spinal anesthesia and a multimodal analgesic regimen. Patients were randomized to receive EXPAREL 266 mg plus bupivacaine HCl 50 mg or bupivacaine HCl 50 mg alone administered via TAP field block after delivery. Effectiveness was evaluated in a pre-specified modified intent-to-treat population which met the study criteria regarding proper administration of TAP and multimodal regimen. Key findings include: Significant reduction in total opioid consumption with EXPAREL plus bupivacaine HCl versus bupivacaine HCl. 52% reduction through 72 hours, the primary endpoint of the study. 49% reduction at one week. 41% reduction of opioid consumption at two weeks, although results did not reach statistical significance. Significantly higher percentage of opioid-spared patients with EXPAREL versus bupivacaine HCl, defined as patients who took no more than one oxycodone 10 mg tablet with no opioid-related side effects through 72 hours. Percentage of opioid-spared patients was 2.2 times higher in the EXPAREL group vs bupivacaine HCl group. Optimized pain control through 72 hours, which was comparable in both groups. Patients in the EXPAREL arm of this study were administered a TAP field block with 10 mL EXPAREL admixed with 10 mL 0.25% bupivacaine HCl and 10 mL normal sterile saline injected bilaterally. Patients in the active comparator arm received a TAP field block with 10 mL 0.25% bupivacaine HCl admixed with 20 mL normal sterile saline injected bilaterally. Research shows nearly nine in 10 mothers and mothers-to-be have concerns about taking opioids during and after childbirth, yet 51% of all C-section patients are prescribed an opioid to manage postsurgical pain. Prior to C-section, all patients in this study received an intrathecal injection of 150 mcg preservative-free morphine for spinal injection in conjunction with single-shot spinal anesthesia using 1.4-1.6 mL bupivacaine HCl 0.75% and 15 mcg fentanyl. Following C-section, patients also received an opioid-sparing multimodal analgesic regimen which consisted of 15 mg of intravenous ketorolac, 1000 mg of IV acetaminophen at the time of skin incision closure, and scheduled oral acetaminophen and ibuprofen beginning 6 hours after skin incision closure for up to 72 hours following surgery. Rescue medication was available upon request and postsurgical opioid consumption was collected. Safety was comparable between study groups, with 64 percent of patients in the EXPAREL group experiencing a treatment-emergent adverse event versus 56 percent of patients in the bupivacaine HCl group. The most common TEAEs include pruritus and nausea; serious TEAEs were rare. There were no fatal TEAEs. Earlier this year, Pacira announced positive topline results for CHOICE, a next-generation C-section trial designed to eliminate the use of spinal morphine in the EXPAREL arm. In the study, EXPAREL achieved its primary endpoint with a statistically significant reduction in total opioid consumption while maintaining pain scores through 72 hours, and demonstrated statistical significance for the key secondary endpoint of a reduction in the incidence and severity of itching for 72 hours after surgery.

07:36 EDT Palatin completes enrollment in Phase 2 Study with PL9643 - Palatin Technologies announced completion of enrollment of its Phase 2 study with PL9643 for the treatment of dry eye disease. After delaying enrollment of new patient groups due to the COVID-19 pandemic, Palatin reinitiated enrollment in its PL9643 Phase 2 clinical study in subjects with dry eye disease last month. With enrollment completed, data readout is targeted for the fourth quarter of calendar year 2020.

07:32 EDT Tradeweb Markets reports ADV of $724.7B in July, down 3.5% - Tradeweb Markets reported average daily volume, or ADV, of $724.7B in July, a decrease of 3.5% year-over-year. Tradeweb set new ADV records in global repo trading of $248.5B, which was up 17.7% YoY, and in Chinese bond trading of $1.4B, which rose 41% YoY. In addition, July was the second best month in terms of TRACE credit share for both U.S. high-grade and high-yield.

07:31 EDT Horizon Therapeutics reports Q2 TEPEZZA net sales $165.9M - Horizon Therapeutics said in its Q2 earnings release, "the Company increased its peak U.S. annual net sales estimate for TEPEZZA to greater than $3 billion from the previous estimate of greater than $1 billion, as well as increased full-year 2020 net sales guidance to greater than $650 million from greater than $200 million. Several factors have contributed to the increased expectations, including the severity of TED, which is a motivating factor for patients seeking treatment; the Company's market education efforts to increase awareness of TED, develop the market and assist with patient access; and a high volume of patient and physician interest driven by the Company's commercial execution."

07:27 EDT Regeneron plans to report REGN-COV2 treatment trials in September - The company said in its earnings release, "Following review from the Independent Data Monitoring Committee of REGN-COV2 Phase 1 safety results, a Phase 3 trial to evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient (such as the patient's housemate) was initiated and is being run jointly with the National Institute of Allergy and Infectious Diseases. In addition, REGN-COV2 moved into the Phase 2/3 portion of two adaptive Phase 1/2/3 trials testing the cocktail's ability to treat hospitalized and non-hospitalized patients with COVID-19. The Company plans to report initial virology and biomarker results from the REGN-COV2 treatment trials in September 2020."

07:24 EDT Hepion Pharmaceuticals announces first NASH patient dosed with CRV431 - Hepion Pharmaceuticals announced that CRV431 was administered to the first NASH patient. Hepion previously announced that CRV431 successfully progressed through a phase 1 program, where the safety, tolerability and pharmacokinetics of CRV431 were evaluated in healthy subjects. The open-label phase 2a study, called the 'AMBITION' trial, is designed to assess safety, tolerability and pharmacokinetics of 75 mg CRV431, administered orally to F2 and F3 NASH patients, once daily for 28 days. Additionally, its clinical pharmacology group will be examining certain biomarkers including, for example, collagen, matrix metalloproteinases, lipidomics, genomics, liver transaminases, Pro-C3, ELF score, gene-gene, gene-protein network analysis and Fibroscan in a multivariate multi-omics analysis to elucidate CRV431 activity in NASH. AI-POWR, Hepion's in-house proprietary big data analytics platform that allows for precision medicine will be used to optimize the understanding of CRV431 in NASH.

07:23 EDT Sabre partners with ASKY - West-African airline, ASKY, has signed a multi-year agreement with Sabre, enabling the carrier to move forward with innovative, next-generation technologies that will facilitate further expansion. The agreement will allow ASKY to leverage the global travel technology leader's passenger service system and its recently-launched Sabre Commercial Platform - the industry's only intelligent retailing platform. Under the new agreement, ASKY will expand its shopping and payment capabilities, improve airport operations and offer a superior experience to travellers. The carrier will also make use of Sabre's Revenue Optimiser, a real-time revenue management solution.

07:22 EDT Evergy reveals transformation plan with 6%-8% EPS growth through 2024 - Evergy announced its new "Sustainability Transformation Plan" to drive "increased value and benefits for all of the Company's stakeholders, including Evergy's shareholders, customers, employees and the communities it serves." The plan was unanimously approved by Evergy's board and follows an independent review that began earlier this year and was conducted by the Board's Strategic Review & Operations Committee. The plan is built around the following key tenets: Increasing investments in critical utility infrastructure to unlock significant operational efficiencies and keep customer electricity rates competitive; Optimizing capital allocation to create a stronger grid for the future; Accelerating Evergy's transition to a clean energy provider. Under the company's new plan, Evergy expects $8.9B of base capital investments through 2024, or approximately $1.4B more than its prior plan. The company is targeting earnings compounded annual growth of 6% to 8% through 2024, compared to its previous target of 5% to 7% through 2023. Evergy expects dividend growth in line with earnings growth targeting a payout ratio of 60% to 70%. Evergy plans to generate total annual shareholder returns of 9% to 11% through 2024. Since closing its merger, Evergy has achieved in excess of $250M of merger savings, "well ahead of its original target," the company notes.

07:21 EDT Discovery reports Q2 adjusted OIBDA down 12% to $1.127B - Q2 free cash flow was $879M.

07:18 EDT Teva, Alvotech announce partnership to commercialize five biosimilar candidates - Teva and biopharmaceutical company Alvotech announced that they have entered into an exclusive strategic partnership for the commercialization in the U.S. of five biosimilar product candidates. This strategic partnership combines Teva's commercial presence and infrastructure in the U.S. market with Alvotech's scientific experience and biologics manufacturing. The initial pipeline contains biosimilar candidates addressing multiple therapeutic areas. Under this partnership agreement, Alvotech will be responsible for the development, registration and supply of the biosimilars, while Teva will be exclusively commercializing the products in the U.S. The originator products of these five candidates currently generate around $35B in U.S. sales. The agreement includes an upfront payment, with subsequent milestone payments over the next several years. Teva and Alvotech will share profit from the commercialization of the biosimilars. All other financial terms and product details remain confidential.

07:15 EDT Kinnevik announces support for proposed Teladoc Health and Livongo merger - Kinnevik AB, which is today the second largest shareholder in Livongo, holding 13% of outstanding shares corresponding to 11% on a fully diluted basis, announced that it supports the proposed merger between Teladoc Health (TDOC) and Livongo Health (LVGO). When the merger has been completed, Kinnevik will become an owner of a 4.5% stake in the combined company and receive $143M in cash consideration. The merger consideration values Kinnevik's stake in Livongo at approximately $2.0B, up $183M from the value of Kinnevik's stake in Livongo at August 4, 2020 close.

07:15 EDT Constellation expects cash to fund operations in mid-2023 - Constellation expects that its current cash, cash equivalents, and marketable securities will fund operations into mid-2023.

07:13 EDT Bausch Health resolves Canadian securities class action - Bausch Health announced that the parties in the Canadian securities class action have agreed to resolve the Action for approximately $69M, plus an additional amount for settlement administration costs, subject to court approval. The Action, filed in the Quebec Superior Court in 2015, alleged violations of Canadian securities laws regarding substantively the same matters as in the U.S. securities class action, which the company also successfully settled. Once approved by the court, the settlement will resolve and discharge all class claims against the company and the other defendants in the Action. "This Settlement, together with our U.S. securities class action settlement and recent successful resolution of the legacy SEC investigation, puts an end to several of the more significant legal matters from the Valeant era and enables us to continue to focus our attention on Bausch Health today and our future," said Joseph Papa, chairman and CEO of Bausch Health. As part of the Settlement, the company and the other defendants admit no liability and deny all allegations of wrongdoing whatsoever.

07:07 EDT Wayfair reports 26M active customers as of June 30 - Wayfair said in its Q2 earnings release, "The number of active customers in our Direct Retail business reached 26 million as of June 30, an increase of 46.0% year over year. LTM net revenue per active customer was $440 as of June 30, a decrease of 1.6% year over year. Orders per customer, measured as LTM orders divided by active customers, was 1.89 for the second quarter of 2020, compared to 1.86 for the second quarter of 2019. Repeat customers placed 67.4% of total orders in the second quarter of 2020, compared to 67.8% in the second quarter of 2019. Repeat customers placed 12.7 million orders in the second quarter of 2020, an increase of 104.9% year over year. Orders delivered in the second quarter of 2020 were 18.9 million, an increase of 106.2% year over year. Average order value was $227 for the second quarter of 2020, compared to $255 for the second quarter of 2019. In the second quarter of 2020, 60.6% of total orders delivered for our Direct Retail business were placed via a mobile device, compared to 53.5% in the second quarter of 2019."

07:01 EDT Discovery expects to resume share repurchases at end of blackout period - Discovery said, "In February 2020, the company's Board of Directors authorized common stock repurchases of up to $2 billion. Under the stock repurchase authorization, management is authorized to purchase shares from time to time through open market purchases at prevailing prices or privately negotiated purchases subject to market conditions and other factors. During the three months ended June 30, 2020, the company did not repurchase any shares under its $2 billion repurchase authorization, which has $1.8 billion remaining. We expect to resume repurchasing shares in the open market once the blackout period ends on August 6, 2020."

07:00 EDT Blackstone to buy 75% stake in Ancestry.com in $4.7B deal, Bloomberg says - Blackstone Group is planning to purchase roughly 75% of Ancestry.com in a deal valued at $4.7B including debt, Bloomberg's Heather Perlberg reports, citing people familiar with the transaction. The acquisition will be the first by the asset manager;s largest ever private equity fund and Singaporean sovereign-wealth fund GIC Pte, which took stake in 2016, will hold about 25%. Reference Link

06:57 EDT BorgWarner building iDM for Ford Mustang Mach-E SUV - BorgWarner (BWA) said in a release, "BorgWarner is building a power-packed Integrated Drive Module, or iDM, for Ford's (F) new all-electric Mustang Mach-E SUV. The iDM comes complete with a BorgWarner thermal-management system and gearbox integrated with a motor and power electronics from other suppliers, and showcases the company's system integration expertise. The iDM is being supplied to power the Mustang Mach-E's rear-wheel drive and all-wheel-drive configurations. On the all-wheel-drive GT version, BorgWarner is supplying the secondary drive unit to power the front wheels as well. Start of production is slated to begin this year. The iDM comes complete with a BorgWarner gearbox integrated with a motor and power electronics from other suppliers, and showcases the company's extensive knowledge of system integration."

06:55 EDT Regeneron reports Q2 EYLEA U.S. net sales $1.11B vs. $1.16B last year - Regeneron (REGN) said in its Q2 earnings release, "EYLEA net product sales in the United States were $1.114 billion in the second quarter of 2020, compared to $1.160 billion in the second quarter of 2019. EYLEA's second quarter 2020 net product sales in the United States were negatively impacted by the COVID-19 pandemic. Overall distributor inventory levels for EYLEA in the United States remained within the Company's one-to-two-week targeted range. Total revenues also include Sanofi (SNY) and Bayer (BAYRY) collaboration revenues of $513 million in the second quarter of 2020, compared to $353 million in the second quarter of 2019. Sanofi collaboration revenue increased primarily due to the Company's share of profits from commercialization of antibodies, which increased to $172 million in the second quarter of 2020 from $39 million in the second quarter of 2019. The change in the Company's share of profits from collaboration antibodies was primarily driven by higher Dupixent profits."

06:51 EDT UnitedHealth authorizes cash dividend of $1.25 per share - The UnitedHealth Group board of directors has authorized payment of a cash dividend of $1.25 per share, to be paid on September 22 to all shareholders of record of UnitedHealth Group common stock as of the close of business on September 14.

06:49 EDT BorgWarner reports Q2 Engine segment net sales $826M vs. $1.57B last year - BorgWarner said in its Q2 earnings release, "Engine segment net sales were $826 million in the second quarter 2020 compared with $1,569 million in the second quarter 2019. Excluding the impact of foreign currencies, net sales were down 46% from the prior year. Adj. earnings before interest, income taxes and non-controlling interest ("Adj. EBIT") were $28 million in the second quarter 2020, compared to $249 million from the prior year. The decline in Adj. EBIT was primarily due to the impact of lower revenue. Excluding the impact of foreign currencies, Adj. EBIT was $29 million, down $220 million from the second quarter 2019."

06:43 EDT FMC Corporation sees FY20 adj. cash from operations $700M-900M - Up 26% from FY19.

06:37 EDT CVS Health reports Q2 total SSS up 2.4% - Reports Q2 pharmacy SSS up 4.6%. Reports Q2 Front Store SSS down 4.5%. Reports Q2 prescription volume 0.6%. Reports Q2 generic dispensing rate 89.1%.

06:27 EDT FMC Corporation expects to resume share repurchases in Q4

06:14 EDT ForeScout, Arista Networks announce strategic partnership - Forescout Technologies (FSCT) announced a strategic partnership with Arista Networks (ANET) to reduce cybersecurity risks brought on by explosive growth of IoT devices, increased network complexity and propagation of malware. The partnership includes the development of a unique open ecosystem that embeds security within the network fabric and delivers full visibility and enforcement of critical enterprise assets. Through this new collaboration, Forescout integrates directly to and is certified on Arista's switches and wireless infrastructure, including the new line of Arista Cognitive Campus PoE switches. Forescout also supports Arista's network-wide workload orchestration and workflow automation solution CloudVision. Further, co-innovation is underway in the context of a Zero Trust architecture to identify IoT devices and ensure they are assigned to specific segments in order to reduce risk and prevent anomalous behavior.

06:11 EDT Lumber Liquidators says Q2 'significantly affected by COVID-19' - Lumber Liquidators said in its Q2 earnings release, "The second quarter of 2020 was significantly affected by the COVID-19 pandemic, but the Company remained focused on serving its customers while keeping the health and safety of employees' and customers' paramount. The Company operated in a variety of operating models (fully open, curbside-pickup, online) during the quarter and utilized safety measures such as personal protective equipment for employees and customers. Additional measures included contact-free and appointment-based engagement with customers, adding barriers at registers and social distancing signage and guidelines to stores. These practices were implemented to comply with state and local ordinances along with recommendations from the CDC and State Boards of Health. By early July, 98% of stores were fully open, with less than 10 operating by appointment only. Only one store remained closed since the onset of the pandemic due to a unique store design while others closed periodically as warranted by market conditions. As reported in the Company's first quarter earnings release, quarter-to-date comparable store sales were down approximately 30% through the week ended May 23. Improving performance in June resulted in a negative 21.3% comparable store sales for the full quarter. Throughout the quarter, the Company leveraged strategic investments in digital capabilities made over the past 18 months, including the Floor Finder and Picture It! tools, to serve customers at LLFlooring.com. Web traffic has increased meaningfully, particularly when store showrooms had limited availability. The Company has also expanded availability of online flooring samples and extended hours for voice and click-to-chat customer support, while also continuing to offer curbside store pickup and enhanced home-delivery options. In April, as a result of reduced demand and the changes in operating models due to COVID-19, the Company temporarily furloughed a number of store associates and reduced operating hours in its distribution centers. As demand returned through the quarter, the Company recalled associates, and as of late June, had invited all furloughed employees back to work and had returned to normal operations in its distribution centers. The Company implemented a range of other measures to increase financial flexibility and maintain agility during this challenging time. As a result of improved business trends, the temporary reduction in all salaried corporate employees' and Board of Directors' compensation ended effective July 1."

06:09 EDT Vertiv Holdings says 'set-up nicely' for 2021 - The company said, "While the dynamic nature of COVID-19 makes visibility challenged in some regards, we expect sales growth to continue in the cloud, colocation and telecom market segments. Additionally, as we strive to maintain fixed costs constant in 2021, we anticipate announcing restructuring activities during the third quarter which could drive a $50 - $70 million reduction in fixed costs plus additional variable cost benefit. We estimate cash costs of $50 - $70 million including capital to realize these benefits, and we will evaluate these cash costs for a likely restructuring reserve to be recorded in the third quarter. A combination of top-line growth with margin expansion plans will set-up the company nicely for 2021."

06:05 EDT Patterson-UTI reports an average of 60 drilling rigs operating in July

06:03 EDT GCP Applied Technologies announces $100M stock repurchase program - GCP Applied Technologies said in its Q2 earnings release, "On July 30, the board of GCP authorized a program to repurchase up to $100 million of the Company's common stock which is effective through July 30, 2022. Share repurchases under the program may be made from time to time at the Board's discretion through open market purchases or privately negotiated transactions in accordance with applicable federal securities laws, including Rule 10b-18 of the Exchange Act. The share repurchase program is subject to a periodic review by the Board and may be suspended periodically or discontinued at any time. The Company plans to fund repurchases from its existing cash balance. No shares have been repurchased by the Company subsequent to July 30."

05:33 EDT Cedar Fair reports initial attendance after reopening below expectations - Cedar Fair said in its Q2 earnings release, "The Company noted that initial attendance upon the reopening of its parks has been below original expectations, likely reflecting the public's continued concerns around the COVID-19 pandemic. The Company also noted the timing of park openings from mid-June through mid-July coincided with growing concerns about recent spikes in COVID-19 cases and hospitalizations across a wide swath of the country. 'Based on the soft demand trends, we have removed our reservation system and adjusted park calendars and operating models to better align with attendance levels, while remaining focused on providing guests with the best possible experience when visiting our parks,' said CEO Richard Zimmerman. 'Health concerns in the marketplace around the pandemic could present a headwind for attendance until consumer confidence improves. Until such time, we are staying engaged with our customers while offering guests the best possible entertainment experience within the required safety protocols. Additionally, the learnings and experience from current park operations are invaluable to our team as we reassess operating plans and strategies for the 2021 season and beyond.' Zimmerman added that the Company remains committed to emerging stronger from the pandemic by strengthening the brand reputation of its parks with stakeholders, positioning its parks to remain the top choice for safe, family entertainment in the new reality, and maintaining the strong underlying economics of its business model."

05:19 EDT Fiverr sees Q3 revenue $48M-$49M, consensus $37.94M - Sees Q3 adjusted EBITDA $2M-$3M.